Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orca-Q in Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies
NCT03802695Phase 1Recruiting
- Sponsor
- Orca Bio
- Start
- Apr 2019
- Primary completion
- Dec 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of Orca-Q in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), mixed phenotype acute leukemia (MPAL) and 1 more (6 arms), sponsored by Orca Bio. Primary endpoints: Dose Limiting Toxicities at 28 days and Primary Graft failure at 28 days. Started Apr 2019; status: recruiting.
02
Drugs
Orca-Q
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)mixed phenotype acute leukemia (MPAL)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03802695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03802695.